PRKCA - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
KCNE1	potassium voltage-gated channel subfamily E regulatory subunit 1	Phase 3 - rapid repolarisation Phase 2 - plateau phase	Enflurane Promethazine Miconazole Azimilide	Long QT syndrome, including: Romano-Ward syndrome; Jervell and Lange-Nielsen syndrome (JLNS)
KCNE4	potassium voltage-gated channel subfamily E regulatory subunit 4	Phase 3 - rapid repolarisation Phase 2 - plateau phase	Enflurane Promethazine Miconazole
KCNQ2	potassium voltage-gated channel subfamily Q member 2	Voltage gated Potassium channels Interaction between L1 and Ankyrins	Enflurane Amitriptyline Meclofenamic acid Promethazine Miconazole Ezogabine ICA-105665	Early infantile epileptic encephalopathy; Ohtahara syndrome
KIT	KIT proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Regulation of KIT signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Dasatinib-resistant KIT mutants Imatinib-resistant KIT mutants KIT mutants bind TKIs Masitinib-resistant KIT mutants Nilotinib-resistant KIT mutants Regorafenib-resistant KIT mutants Signaling by kinase domain mutants of KIT Sunitinib-resistant KIT mutants Signaling by juxtamembrane domain KIT mutants Sorafenib-resistant KIT mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by extracellular domain mutants of KIT Transcriptional and post-translational regulation of MITF-M expression and activity Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells	Sorafenib Imatinib Dasatinib Sunitinib Phosphonotyrosine Nilotinib XL820 OSI-930 Linifanib Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Ancestim Tivozanib Fostamatinib Erdafitinib Amuvatinib Pexidartinib Ripretinib Avapritinib	Acute myeloid leukemia (AML) Piebaldism
KLF5	KLF transcription factor 5	Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of granulopoiesis
KRT18	keratin 18	Keratinization Formation of the cornified envelope Developmental Lineage of Mammary Gland Luminal Epithelial Cells Developmental Lineage of Mammary Gland Alveolar Cells
LCK	LCK proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Nef Mediated CD4 Down-regulation Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling Co-stimulation by CD28 CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway Co-inhibition by CTLA4 Co-inhibition by PD-1 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling RHOH GTPase cycle Interleukin-2 signaling Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases	Dasatinib AP-22408 Staurosporine 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid Phosphoaminophosphonic Acid-Adenylate Ester 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine Ponatinib Nintedanib Fostamatinib Zanubrutinib Zotiraciclib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
LMNA	lamin A/C	XBP1(S) activates chaperone genes Signaling by BRAF and RAF1 fusions		Mandibuloacral dysplasia Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Limb-girdle muscular dystrophy (LGMD) Hutchinson-Gilford progeria syndrome Restrictive dermopathy Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
LMNB1	lamin B1	Meiotic synapsis Formation of Senescence-Associated Heterochromatin Foci (SAHF) Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina Depolymerization of the Nuclear Lamina Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation RHOD GTPase cycle RHOF GTPase cycle
MAPKAP1	MAPK associated protein 1	PIP3 activates AKT signaling CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
MAPT	microtubule associated protein tau	Caspase-mediated cleavage of cytoskeletal proteins	Lansoprazole Astemizole Paclitaxel Docetaxel Flortaucipir F-18	Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3) Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
MARCKS	myristoylated alanine rich protein kinase C substrate	Acetylcholine regulates insulin secretion
MBP	myelin basic protein	EGR2 and SOX10-mediated initiation of Schwann cell myelination
MGMT	O-6-methylguanine-DNA methyltransferase	MGMT-mediated DNA damage reversal	Cysteine Zinc S-Methylcysteine S-Benzylcysteine Dinitrochlorobenzene Zinc acetate Zinc chloride Zinc sulfate, unspecified form
MTOR	mechanistic target of rapamycin kinase	PIP3 activates AKT signaling Macroautophagy MTOR signalling mTORC1-mediated signalling HSF1-dependent transactivation Energy dependent regulation of mTOR by LKB1-AMPK CD28 dependent PI3K/Akt signaling VEGFR2 mediated vascular permeability TP53 Regulates Metabolic Genes Constitutive Signaling by AKT1 E17K in Cancer Regulation of TP53 Degradation Regulation of PTEN gene transcription Amino acids regulate mTORC1 High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	Pimecrolimus Sirolimus Everolimus Rimiducid SF1126 XL765 Ridaforolimus Temsirolimus GSK-1059615 Fostamatinib Oleandrin
MYLK	myosin light chain kinase	Smooth Muscle Contraction RHO GTPases activate PAKs RHO GTPases activate PAKs	Ritodrine Fostamatinib	Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
MYOD1	myogenic differentiation 1	Myogenesis Myogenesis TGFBR3 expression
NCF1	neutrophil cytosolic factor 1	ROS and RNS production in phagocytes Cross-presentation of particulate exogenous antigens (phagosomes) Detoxification of Reactive Oxygen Species VEGFA-VEGFR2 Pathway RHO GTPases Activate NADPH Oxidases RAC1 GTPase cycle RAC2 GTPase cycle RAC3 GTPase cycle	Dextromethorphan	Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
NF2	NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor	Regulation of actin dynamics for phagocytic cup formation RHO GTPases activate PAKs		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Malignant pleural mesothelioma
NFATC1	nuclear factor of activated T cells 1	Calcineurin activates NFAT Calcineurin activates NFAT FCERI mediated Ca+2 mobilization Ca2+ pathway CLEC7A (Dectin-1) induces NFAT activation Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells)	Pseudoephedrine

Search Results for: PRKCA